Teva gives up on turning Nuvigil into an antidepressant

Teva Pharmaceutical Industries ($TEVA) scrapped its plans to develop Nuvigil as a treatment for depression. The drug, originally approved to treat sleep apnea, had failed another Phase III trial. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.